Korean office
BioTek Instruments has established BioTek Korea, which the company reports will focus on growing the brand, and expanding direct service and application support for customers in South Korea.
BioTek Instruments has established BioTek Korea, which the company reports will focus on growing the brand, and expanding direct service and application support for customers in South Korea.
"The establishment of BioTek Korea will allow BioTek to increase our investment of resources in this very important marketplace," commented Briar Alpert, company president and CEO. "In addition to providing incremental local service and application support, our customers in South Korea will have direct access to the company's global scientific and applications resources. Ultimately, this will lead to enhanced customer satisfaction for our Korean customers."
The office will be fully functional by 1 July 2011.
For more information visit www.biotek.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
